ISEE2008

A Phase 3 Multicenter, Randomized, Double-Masked, Sham controlled Clinical Trial To Assess The Safety And Efficacy Of Intravitreal Administration Of Zimura™ (Complement C5 Inhibitor) In Patients With Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

Study Type  : Interventional  (Clinical Trial)
Actual Enrollment  : 448 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Masking Description: Participant, “Evaluating” Investigator, Reading Center Personnel, and Sponsor Personnel are masked
Primary Purpose: Treatment
Official Title: A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Actual Study Start Date  : June 29, 2020
Estimated Primary Completion Date  : July 2022
Estimated Study Completion Date  : July 2023

Related Publications

Our Affiliates